DAIC
MARCH 13, 2024
CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. The CardiAMP Heart Failure II Trial is FDA approved to enroll up to 250 patients at up to 40 clinical centers. said Peter Altman , PhD.,
DAIC
MARCH 7, 2024
Results showed reductions in heart death equivalents and MACCE, with a magnified reduction among patients with elevated NTproBNP, a common marker of heart distress. These patients saw more than a 17% lower rate of heart death equivalents at up to two years compared to control patients treated with heart failure medication alone (2.9%
DAIC
JULY 25, 2024
FDA granted CardiAMP Cell Therapy a Breakthrough Device Designation for the treatment of ischemic heart failure. Leslie Miller, MD , trial investigator at the CHF Heart Function Clinic at BayCare Morton Plant Hospital in Clearwater, Florida and a member of the CardiAMP Heart Failure II Study Executive Steering Committee. “As
DAIC
JULY 1, 2024
Adamson, MD, MSc, FACC, FESC, FRCP (Ed ) has been appointed as Chief Medical Officer, Bonnie Handke, RN, MBA will assume the role of Senior Vice President of Patient Access, Reimbursement, and Healthcare Economics, and Jennifer E. Englund recently joined as Senior Vice President of Global Clinical Affairs. Handke earned an MBA from St.
DAIC
JULY 31, 2024
In its announcement about the workbook, ACC noted that cardiologists use digital devices and wearable technology to remotely monitor their patients for a variety of chronic cardiovascular diseases, including heart failure, coronary artery disease, vascular disease and atrial fibrillation. Food and Drug Administration authorization.
DAIC
FEBRUARY 1, 2024
The article also includes links to DAIC channels (on peripheral artery disease, stroke, heart failure, peripheral artery disease, cardiovascular clinical studies, and more) focused on specific areas of news coverage. People with diabetes are twice as likely to have heart disease or a stroke than people without diabetes. -
DAIC
JANUARY 16, 2024
There, he served as an investigator in many high-profile clinical trials, including several significant structural heart studies. Dr. Shreenivas is a frequent speaker at major scientific meetings and has been widely published in peer-reviewed journals across the structural heart, heart failure, and coronary arenas.
Expert insights. Personalized for you.
111 
Let's personalize your content